Ali Fattaey
CEO
Your CSV is on the way
We’ve sent your CSV file to email@email.com
Claimed by
owner Add to list
Metabomed
Former names:
Target-inhibiting Anticancer Drugs
Stealth Mode
May 2024 ceased to operate
Metabomed
Metabomed Overview
Metabomed is a drug-discovery company in the field of cancer metabolism, with a proprietary target-identification platform based on computational biology and metabolomics. The company focuses on developing drugs that inhibit targets that form a synthetic lethal gene pair with metabolic genes inactivated in cancer cells.
Using this target-inhibiting strategy, Metabomed intends to develop more selective, highly focused anticancer drugs with the ability to kill cancer cells without harming normal cells.
Using this target-inhibiting strategy, Metabomed intends to develop more selective, highly focused anticancer drugs with the ability to kill cancer cells without harming normal cells.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Metabomed Climate Tech relevance
null
No Data, yet.
Sorry, no content found under this section.
Sep 9, 2020
www.marketscreener.com
MetaboMed Appoints Ali Fattaey, Ph.D. as Chief Executive Officer
#Management Changes
Dec 19, 2019
en.globes.co.il
Targeted cancer therapy co Metabomed raises $12.5m
#Investment
Apr 4, 2016
www.globes.co.il
Cancer metabolism co Metabomed raises $18m
#Investment
Companies you might be interested in
Driven by Finder AI
Primary sector
Total funding
Funding stage
Number of employees
Founded
Related Content
Lists. Maps. Reports
Team Members
AF
EG
Contact Team
Affiliated Organizations
(null)Web & social links
Locations
Israel
HaKishon Street 18, Yavne, Israel
Offices Abroad
One Broadway, Cambridge, MA USA
Photos & videos
(0)No Data, yet.
Sorry, no content found under this section.
Metabomed Business
Sector
Primary:
Health Tech & Life Sciences
Target Customer
Core Technology
Use Cases
(0)Tech Community Involvement
(0)Metabomed Financials
Cumulative Funding Raised Over Time ($)
No Data, yet.
Sorry, no content found under this section.
Public Offerings & Exits
Private Equity Funding
Undisclosed Round
Undisclosed
Apr 2022
1
Investors
Undisclosed
Undisclosed Round
$12.5M
Dec 2019
6
Investors
$12.5M
Lead
Yonjin Ventures
VC and Private Equity
UK
Boehringer Ingelheim Venture Fund
VC and Private Equity
Follow on
Germany
M Ventures
Corporate VC
Follow on
Netherlands
Pontifax
VC and Private Equity
Follow on
Israel
Arkin Bio
VC and Private Equity
Follow on
Israel
Pfizer Ventures
Corporate VC
Follow on
United States
A Round
$18M
Apr 2016
6
Investors
$18M
M Ventures
Corporate VC
Follow on
Netherlands
Pontifax
VC and Private Equity
Israel
Boehringer Ingelheim Venture Fund
VC and Private Equity
Germany
Pfizer Ventures
Corporate VC
United States
Technion Research & Development Foundation
VC and Private Equity
Israel
Arkin Bio
VC and Private Equity
Israel
Non-Equity Funding
Mergers and Acquisitions
Metabomed Lifecycle
Cumulative Funding Raised Over Time ($)
Timeline
Employees Over Time
News Over Time
No Data, yet.
Sorry, no content found under this section.
Closing Event
May 2024
Undisclosed Round
Undisclosed
Apr 2022
1
Investors
Undisclosed
Undisclosed Round
$12.5M
Dec 2019
6
Investors
$12.5M
Lead
Yonjin Ventures
VC and Private Equity
UK
Boehringer Ingelheim Venture Fund
VC and Private Equity
Follow on
Germany
M Ventures
Corporate VC
Follow on
Netherlands
Pontifax
VC and Private Equity
Follow on
Israel
Arkin Bio
VC and Private Equity
Follow on
Israel
Pfizer Ventures
Corporate VC
Follow on
United States
A Round
$18M
Apr 2016
6
Investors
$18M
M Ventures
Corporate VC
Follow on
Netherlands
Pontifax
VC and Private Equity
Israel
Boehringer Ingelheim Venture Fund
VC and Private Equity
Germany
Pfizer Ventures
Corporate VC
United States
Technion Research & Development Foundation
VC and Private Equity
Israel
Arkin Bio
VC and Private Equity
Israel
Metabomed News
News Over Time
No Data, yet.
Sorry, no content found under this section.
News Articles
Sep 9, 2020
www.marketscreener.com
MetaboMed Appoints Ali Fattaey, Ph.D. as Chief Executive Officer
#Management Changes
Dec 19, 2019
en.globes.co.il
Targeted cancer therapy co Metabomed raises $12.5m
#Investment
Apr 4, 2016
www.globes.co.il
Cancer metabolism co Metabomed raises $18m
#Investment
Related Content
Metabomed Team
No Data, yet.
Sorry, no content found under this section.
Employees Over Time
Companies you might be interested in
Driven by Finder AI
Metabomed Internal
Create note
Notes
(undefined)
Filter notes
Content Writer
undefined
BI Verification
undefined
Phone Number
undefined
Israel Register ID
undefined
Confidence Score
undefined
Missing Fields
undefined
Profile Creator
undefined
Profile Update
undefined
undefined
Access Comprehensive Financial Analytics
Create a free account to:
- Explore detailed financial analytics.
- Track company growth and size.
- Connect with company team members.
I already have access,
I already have access,